专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080214437A1 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases 审中-公开
标题翻译：用于降低心房钠尿肽受体活性和治疗疾病的方法和组合物
公开(公告)号：US20080214437A1
公开(公告)日：2008-09-04
申请号：US11998792
申请日：2007-11-30
申请人： Shyam S. Mohapatra , Weidong Xu , Xiaoyuan Kong , Xiaoqin Wang , Subhra Mohapatra
发明人： Shyam S. Mohapatra , Weidong Xu , Xiaoyuan Kong , Xiaoqin Wang , Subhra Mohapatra
IPC分类号： A61K38/02 , C07K2/00 , A61K31/711 , A61P31/12 , A61P35/00 , A61P29/00 , C12N5/06 , C07H21/04
CPC分类号： C12N15/1138 , A61K9/0019 , A61K9/0034 , A61K9/0043 , A61K9/0073 , A61K9/5161 , A61K31/711 , A61K31/713 , A61K47/61 , A61K47/6935 , A61K47/6939 , A61K48/0008 , A61K48/005 , A61K49/0008 , B82Y5/00 , C12N2310/11 , C12N2310/111 , C12N2310/14 , C12N2320/30
摘要： Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of these therapies. Routes used for delivering polynucleotides encoding a natriuretic peptide, or, for example, siRNA that down regulates natriuretic peptide receptor include subcutaneous injection, oral gavage, transdermal and intranasal delivery routes. Compositions can include chitosan, chitosan derivatives, and chitosan derivative and a lipid. Transdermal delivery can use a transdermal cream. Intranasal delivery can use a dropper or an aspirator for delivery of a mist. Oral gavage delivers equivalent to oral delivery. Delivery permits cell and tissue specific targeting of gene therapies resulting in expression of a natriuretic peptide or down regulation of natriuretic peptide receptor. A variety of cancers, asthma and viral diseases can be treated therapeutically using the methods and compositions of the present invention.
摘要翻译：本发明提供了降低利尿钠肽受体活性和其他信号的方法，组合物和装置。通过使用编码利尿钠肽的多核苷酸或通过调节利尿钠肽受体（如NPRA和NPRC）的表达或这些疗法的组合来提供治疗性治疗。用于递送编码利尿钠肽的多核苷酸的路线，或例如下调调节利尿钠肽受体的siRNA包括皮下注射，口服管饲，透皮和鼻内递送途径。组合物可以包括壳聚糖，壳聚糖衍生物和壳聚糖衍生物和脂质。透皮给药可以使用透皮霜。鼻内输送可以使用滴管或吸气器来传送雾。口服管子相当于口服输送。交付允许基因治疗的细胞和组织特异性靶向导致利尿钠肽的表达或利尿钠肽受体的下调。可以使用本发明的方法和组合物治疗多种癌症，哮喘和病毒性疾病。

2. 发明授权

US08071560B2 Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor 有权
标题翻译：通过抑制心房钠尿肽受体来减少炎症的材料和方法
公开(公告)号：US08071560B2
公开(公告)日：2011-12-06
申请号：US11799225
申请日：2007-04-30
申请人： Shyam S. Mohapatra , Weidong Xu , Xiaoyuan Kong , Xiaoqin Wang
发明人： Shyam S. Mohapatra , Weidong Xu , Xiaoyuan Kong , Xiaoqin Wang
IPC分类号： A61K48/00
CPC分类号： C12N15/1138 , C12N2310/14
摘要： This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and/or ovarian cancer) by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy (such as allergic rhinitis and asthma), viral infection, and/or cancer by administering such NPRA inhibitors to the subject.
摘要翻译：本发明涉及用于减少与诸如哮喘，呼吸道合胞病毒（RSV）感染和癌症相关的许多人类疾病的炎症的小干扰RNA（siRNA）的心房钠尿肽受体A（NPRA）功能的抑制剂（例如黑素瘤，肺癌和/或卵巢癌）通过干扰NPRA基因表达或以其他方式降低受试者内的NPRA功能; 以及通过向受试者施用这种NPRA抑制剂来治疗患有或有风险发展为炎性疾病，呼吸性过敏（例如过敏性鼻炎和哮喘），病毒感染和/或癌症的受试者的方法。

3. 发明申请

US20070265204A1 Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor 有权
标题翻译：通过抑制心房钠尿肽受体来减少炎症的材料和方法
公开(公告)号：US20070265204A1
公开(公告)日：2007-11-15
申请号：US11799225
申请日：2007-04-30
申请人： Shyam Mohapatra , Weidong Xu , Xiaoyuan Kong , Xiaoqin Wang
发明人： Shyam Mohapatra , Weidong Xu , Xiaoyuan Kong , Xiaoqin Wang
IPC分类号： C07H21/04 , C12P21/06
CPC分类号： C12N15/1138 , C12N2310/14
摘要： This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and/or ovarian cancer) by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy (such as allergic rhinitis and asthma), viral infection, and/or cancer by administering such NPRA inhibitors to the subject.
摘要翻译：本发明涉及用于减少与诸如哮喘，呼吸道合胞病毒（RSV）感染和癌症等许多人类疾病相关的炎症的小干扰RNA（siRNA）的心房钠尿肽受体A（NPRA）功能的抑制剂（例如黑素瘤，肺癌和/或卵巢癌）通过干扰NPRA基因表达或以其他方式降低受试者内的NPRA功能; 以及通过向受试者施用这种NPRA抑制剂来治疗患有或有风险发展为炎性疾病，呼吸性过敏（例如过敏性鼻炎和哮喘），病毒感染和/或癌症的受试者的方法。

4. 发明授权

US08293486B2 Functionalization of silk material by avidin-biotin interaction 有权
标题翻译：丝素材料通过抗生物素蛋白 - 生物素相互作用进行功能化
公开(公告)号：US08293486B2
公开(公告)日：2012-10-23
申请号：US13381687
申请日：2010-07-20
申请人： David L. Kaplan , Xiaoqin Wang , Monica A. Serban
发明人： David L. Kaplan , Xiaoqin Wang , Monica A. Serban
IPC分类号： G01N33/53 , C07K1/00
CPC分类号： C07K14/43586 , A61K47/64 , A61K47/6903 , A61K47/6921
摘要： The present invention provides for compositions and methods of linking silk fibroin to active agents through the specific interaction between avidin and biotin, providing for functionalization of silk-based protein biomaterials. An avidin- or biotin-modified silk is a biomaterial platform for functionalization with a variety of correspondingly linked active agents, such as antibodies and growth factors. A variety of functionalized silk materials, such as silk hydrogel, silk micro/nanoparticles and silk films, can be prepared by the methods of the present invention. The functionalization strategies of the present invention are relatively easy, fast and feasible, and are thus useful in many biomedical applications.
摘要翻译：本发明提供通过抗生物素蛋白和生物素之间的特异性相互作用将丝素蛋白与活性剂连接的组合物和方法，提供了基于丝的蛋白质生物材料的功能化。抗生物素蛋白或生物素修饰的丝是用于与多种相应连接的活性剂如抗体和生长因子进行功能化的生物材料平台。可以通过本发明的方法制备各种功能性丝绸材料，例如丝素水凝胶，丝微/纳米颗粒和丝膜。本发明的功能化策略相对容易，快速和可行，因此在许多生物医学应用中是有用的。

5. 发明申请

US20120129255A1 FUNCTIONALIZATION OF SILK MATERIAL BY AVIDIN-BIOTIN INTERACTION 有权
标题翻译：通过AVIDIN-BIOTIN相互作用对丝素材料的功能化
公开(公告)号：US20120129255A1
公开(公告)日：2012-05-24
申请号：US13381687
申请日：2010-07-20
申请人： David L. Kaplan , Xiaoqin Wang , Monica A. Serban
发明人： David L. Kaplan , Xiaoqin Wang , Monica A. Serban
IPC分类号： C07K19/00 , C12N5/0783
CPC分类号： C07K14/43586 , A61K47/64 , A61K47/6903 , A61K47/6921
摘要： The present invention provides for compositions and methods of linking silk fibroin to active agents through the specific interaction between avidin and biotin, providing for functionalization of silk-based protein biomaterials. An avidin- or biotin-modified silk is a biomaterial platform for functionalization with a variety of correspondingly linked active agents, such as antibodies and growth factors. A variety of functionalized silk materials, such as silk hydrogel, silk micro/nanoparticles and silk films, can be prepared by the methods of the present invention. The functionalization strategies of the present invention are relatively easy, fast and feasible, and are thus useful in many biomedical applications.
摘要翻译：本发明提供通过抗生物素蛋白和生物素之间的特异性相互作用将丝素蛋白与活性剂连接的组合物和方法，提供了基于丝的蛋白质生物材料的功能化。抗生物素蛋白或生物素修饰的丝是用于与多种相应连接的活性剂如抗体和生长因子进行功能化的生物材料平台。可以通过本发明的方法制备各种功能性丝绸材料，例如丝素水凝胶，丝微/纳米颗粒和丝膜。本发明的功能化策略相对容易，快速和可行，因此在许多生物医学应用中是有用的。

6. 发明授权

US08483081B2 Method and apparatus for estimating link quality, and link adaption method and apparatus 有权
标题翻译：用于估计链路质量的方法和装置，以及链路适配方法和装置
公开(公告)号：US08483081B2
公开(公告)日：2013-07-09
申请号：US12908333
申请日：2010-10-20
申请人： Xiaoqin Wang , Xin Wang , Masahiro Watanabe , Taiji Kondo
发明人： Xiaoqin Wang , Xin Wang , Masahiro Watanabe , Taiji Kondo
IPC分类号： H04L1/00
CPC分类号： H04L1/20 , H04B17/26 , H04B17/336 , H04L1/0003 , H04L1/0009 , H04L1/0019
摘要： The present invention discloses a method for estimating quality of a link in a broad-band wireless communication system. The method includes: calculating quality indicators of sub-carriers in an input signal of a receiver of the system; clipping the quality indicators of the sub-carriers; and averaging the clipped quality indicators of the sub-carriers to obtain an average value as an estimation result of an effective quality indicator of the link. The present application also discloses an apparatus for estimating quality of a link in a broad-band wireless communication system, an adaption method and apparatus for a link in a broad-band wireless communication system. The methods and apparatus of the present invention can achieve relatively low calculation complexity and high accuracy.
摘要翻译：本发明公开了一种用于估计宽带无线通信系统中链路质量的方法。该方法包括：计算系统的接收机的输入信号中的子载波的质量指标; 削减子载波的质量指标; 对子载波的剪切质量指示符进行平均，以获得作为链路的有效质量指示符的估计结果的平均值。本申请还公开了一种用于估计宽带无线通信系统中的链路的质量的装置，用于宽带无线通信系统中的链路的适配方法和装置。本发明的方法和装置可以实现相对较低的计算复杂度和高精度。

7. 发明授权

US08187616B2 Method for silk fibroin gelation using sonication 有权
标题翻译：使用超声处理丝素蛋白凝胶化方法
公开(公告)号：US08187616B2
公开(公告)日：2012-05-29
申请号：US12601845
申请日：2008-05-29
申请人： Xiaoqin Wang , Jon Kluge , Gary G. Leisk , David L. Kaplan
发明人： Xiaoqin Wang , Jon Kluge , Gary G. Leisk , David L. Kaplan
IPC分类号： A61K9/00 , A61K38/17
CPC分类号： A61K47/42 , A61K9/06 , A61K9/5052 , A61K9/5063 , A61K9/5089 , A61K35/28 , A61K2035/124 , C07K14/43586
摘要： This invention provides for a process of rapidly forming silk fibroin gelation through ultrasonication. Under the appropriate conditions, gelation can be controlled to occur within two hours after the ultrasonication treatment. Biological materials, including viable cells, or therapeutic agents can be encapsulated in the hydrogels formed from the process and be used as delivery vehicles.
摘要翻译：本发明提供了通过超声波快速形成丝素蛋白凝胶化的方法。在适当的条件下，超声波处理后两小时即可控制凝胶化。包括活细胞或治疗剂在内的生物材料可以包封在由该方法形成的水凝胶中并用作输送载体。

8. 发明申请

US20110223153A1 MODIFIED SILK FILMS CONTAINING GLYCEROL 审中-公开
标题翻译：含有GLYCEROL的改性丝状膜
公开(公告)号：US20110223153A1
公开(公告)日：2011-09-15
申请号：US13122837
申请日：2009-10-09
申请人： Shenzhou Lu , Xiaoqin Wang , Fiorenzo Omenetto , David Kaplan
发明人： Shenzhou Lu , Xiaoqin Wang , Fiorenzo Omenetto , David Kaplan
IPC分类号： A61K39/395 , C12N5/071 , A61K47/42 , A61K35/12 , A61K38/02 , A61K31/7088 , A61K38/43 , A61K35/76 , A61P31/00 , A61P31/04 , A61P35/00 , B29D11/00
CPC分类号： A61L27/3604 , A61L27/3804 , A61L27/50 , A61L27/54 , A61L2420/06 , B05D1/30 , B05D3/0254 , B05D3/107 , C08J3/18 , C08J5/18 , C08J2389/00 , C08K5/053 , C12N11/02 , C08L89/00
摘要： The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be into 3-dimentional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels.
摘要翻译：本发明提供了制备水不溶性，韧性，柔韧性丝素蛋白膜的组合物和方法。丝膜包括丝素蛋白和约10％至约50％（w / w）甘油，并且通过完全水性方法制备。可以通过从丝膜中提取甘油并重新干燥来进一步处理延性丝膜。活性剂可以嵌入或沉积在甘油改性丝膜上用于各种医疗应用。膜可以是三维结构，或者作为标签或涂层放置在支撑表面上。本发明的甘油改性丝膜可用于各种应用，例如组织工程，医疗装置或植入物，药物递送，以及食用药物或食品标签。

9. 发明申请

US20100028451A1 SILK MICROSPHERES FOR ENCAPSULATION AND CONTROLLED RELEASE 审中-公开
标题翻译：用于封装和控制释放的SILK微孔
公开(公告)号：US20100028451A1
公开(公告)日：2010-02-04
申请号：US12442595
申请日：2007-09-26
申请人： David L. Kaplan , Xiaoqin Wang
发明人： David L. Kaplan , Xiaoqin Wang
IPC分类号： A61K9/14 , A61K38/02 , A61K31/7088 , A61K39/395 , A61K38/43 , A61K38/16 , A61K38/21 , A61K38/20 , A61K38/28
CPC分类号： A61K38/44 , A61K9/127 , A61K9/16 , A61K9/1658 , A61K9/19 , A61K9/5052 , A61K31/7076 , A61K47/34 , A61K47/42
摘要： A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.
摘要翻译：开发了一种使用脂质囊泡作为模板来制备丝素蛋白微球的方法，以有效地加载活性形式的治疗剂用于控制释放。随后通过使用脱水剂如甲醇或氯化钠除去脂质，得到具有约2μm直径的β-片状结构优势的丝微球结构。治疗剂可以包埋在丝微球中并用于药物制剂中用于控制释放处理。

10. 发明申请

US20130171260A1 SILK MICROSPHERES FOR ENCAPSULATION AND CONTROLLED RELEASE 审中-公开
标题翻译：用于封装和控制释放的SILK微孔
公开(公告)号：US20130171260A1
公开(公告)日：2013-07-04
申请号：US13778402
申请日：2013-02-27
申请人： David L. Kaplan , Xiaoqin Wang
发明人： David L. Kaplan , Xiaoqin Wang
IPC分类号： A61K9/50
CPC分类号： A61K38/44 , A61K9/127 , A61K9/16 , A61K9/1658 , A61K9/19 , A61K9/5052 , A61K31/7076 , A61K47/34 , A61K47/42
摘要： A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.
摘要翻译：开发了一种使用脂质囊泡作为模板来制备丝素蛋白微球的方法，以有效地加载活性形式的治疗剂用于控制释放。随后通过使用脱水剂如甲醇或氯化钠除去脂质，得到具有约2μm直径的β-片状结构优势的丝微球结构。治疗剂可以包埋在丝微球中并用于药物制剂中用于控制释放处理。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式